The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
Semaglutide 對死亡率及 COVID-19 相關死亡的影響:來自 SELECT 試驗的分析。
J Am Coll Cardiol 2024-09-01
Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.
肥胖、心血管疾病,以及Semaglutide 的前景角色:SELECT 試驗的洞察。
Curr Probl Cardiol 2023-12-16
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Semaglutide 在 SELECT 試驗中對非糖尿病肥胖患者的長期減重效果。
Nat Med 2024-05-17
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Semaglutide在肥胖和心血管疾病中的SELECT試驗中的長期腎臨床結果。
Nat Med 2024-05-25
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
Semaglutide對於過重或肥胖但無糖尿病人群血糖回歸和進展的影響:SELECT試驗。
Diabetes Care 2024-06-22
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Semaglutide在SELECT研究中對基線HbA1c和HbA1c變化的超重或肥胖但無糖尿病人群的心血管結果。
Diabetes Care 2024-06-22
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Semaglutide 與肥胖及心臟衰竭患者的心血管結果:SELECT 試驗的預先指定分析。
Lancet 2024-08-24
Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
根據 SELECT 試驗,符合使用 semaglutide 的美國人群心血管事件減少情況。
Am Heart J 2024-08-25
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
心衰竭患者中 Semaglutide 與安慰劑的比較:SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 隨機試驗的綜合分析。
Lancet 2024-09-02